Alkermes plc reported positive topline results from Vibrance‑2, a randomized, double‑blind phase 2 study of alixorexton (formerly ALKS 2680) versus placebo in patients with narcolepsy type 2.
The company hosted an investor webcast and conference call to present the topline data, and furnished a press release as Exhibit 99.1 and an investor presentation as Exhibit 99.2. Information in Item 7.01 and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act.
Alkermes plc (ALKS) reported an insider transaction by its EVP R&D and Chief Medical Officer, Craig C. Hopkinson. On 11/03/2025, he exercised 5,000 employee stock options at $19.34 and, on the same date, sold 9,000 ordinary shares at a weighted average price of $30.3824.
Both the option exercise and the sale were made under a Rule 10b5-1 trading plan adopted on 3/14/2025. The filing notes the sale occurred in multiple transactions at prices ranging from $30.34 to $30.56. Following these transactions, he directly beneficially owned 69,740 ordinary shares. He also reported 40,104 derivative securities (stock options) remaining. The options exercised were fully vested and carry an expiration date of 02/22/2031.
Alkermes plc (ALKS) reported Q3 2025 results with total revenue of $394.2 million, up modestly from $378.1 million a year ago. Product sales rose to $317.4 million, led by VIVITROL $121.1 million, ARISTADA/ARISTADA INITIO $98.1 million, and LYBALVI $98.2 million. Manufacturing and royalty revenue declined to $76.8 million, reflecting the August 2024 expiry of U.S. royalties on INVEGA SUSTENNA.
Operating income was $89.1 million versus $104.8 million, and net income was $82.8 million (diluted EPS $0.49) versus $92.4 million ($0.55). Year-to-date, revenue was $1.09 billion versus $1.13 billion, with net income of $192.3 million versus $220.6 million.
Cash and cash equivalents increased to $616.4 million from $291.1 million at year-end, supported by $350.7 million in operating cash flow for the first nine months. Short-term investments were $494.7 million. The company reduced Medicaid rebate reserves due to lower-than-expected actual rebates, including approximately $25.3 million for VIVITROL and $12.1 million for ARISTADA/ARISTADA INITIO. Shares outstanding were 165.1 million as of October 24, 2025. No repurchases occurred in 2025; $200.0 million remains authorized.
Alkermes plc furnished an update on its business, announcing financial results for the three and nine months ended September 30, 2025 and updating financial expectations for the year ending December 31, 2025.
The company made its press release and the investor presentation available as Exhibits 99.1 and 99.2, respectively, in connection with its conference call on October 28, 2025. The materials are furnished, not filed, under the Exchange Act.
Alkermes plc announced a recommended acquisition of Avadel Pharmaceuticals plc for $18.50 in cash per Avadel share, plus a non-transferable contingent value right (CVR) for a potential $1.50 per share cash payment upon specified milestones. The deal is expected to proceed via a court‑sanctioned scheme of arrangement under Irish law and would make Avadel a wholly owned subsidiary of Alkermes.
Completion is subject to customary approvals, including Avadel shareholder approval, Irish High Court sanction, registration of the court order, and required U.S. antitrust clearances, with completion expected in the first quarter of 2026. Alkermes entered a senior secured bridge term loan facility up to $1,231,459,813.22 to finance the cash consideration; financing is not a condition to closing. The CVR pays $1.50 per share if both FDA approval for the LUMRYZ indication and dismissal with prejudice of specified claims occur by December 31, 2028. The agreement includes customary no‑shop and fiduciary out provisions, an outside date of 9 months (extendable to 12 months for regulatory approvals), and an Avadel expense reimbursement cap of 1% of aggregate cash consideration.
Alkermes (ALKS): EVP R&D and Chief Medical Officer Craig C. Hopkinson reported insider transactions on 10/15/2025. He exercised 5,000 options at an exercise price of $19.34 and sold 9,000 ordinary shares at a weighted average price of $31.5307 (sold in multiple trades ranging from $31.51 to $31.60). Both the option exercise and the sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025. Following these transactions, he directly beneficially owned 73,740 ordinary shares; derivative securities beneficially owned were 45,104.
Joshua Reed, SVP and Chief Financial Officer, reported equity awards in a Form 4 filed for Alkermes plc (ALKS). On 10/08/2025 he was granted an employee stock option covering 158,743 ordinary shares with an exercise price of $31.51 and a restricted stock unit (RSU) award for 36,656 ordinary shares. Both awards were reported as acquired on the same date and are direct holdings. The option shares vest in four equal annual installments beginning 10/08/2026, and the RSUs vest on the same four-year schedule. Following the transactions, Mr. Reed beneficially owns 158,743 options and 36,656 RSUs. The Form 4 was signed on 10/10/2025.
Joshua Reed, Senior Vice President and Chief Financial Officer of Alkermes plc (ticker ALKS), submitted an initial Form 3 reporting his relationship to the issuer and stating that no securities are beneficially owned as of the reported event date. The filing cites the event date of 09/15/2025 and is signed on behalf of Mr. Reed by an attorney-in-fact, Shantale Greenson, on 09/23/2025. The form includes an exhibit listing a Power of Attorney (Exhibit 24.1) and contains standard Section 16(a) reporting information without disclosure of any direct or indirect holdings or derivative positions.
Alkermes plc furnished an update related to its narcolepsy program. The company issued a press release detailing safety and efficacy results from Vibrance-1, its phase 2 study of alixorexton (formerly ALKS 2680) versus placebo in patients with narcolepsy type 1. The update coincides with Alkermes’ participation at the World Sleep Congress held September 5–10, 2025.
The press release, an investor presentation and scientific presentations are included as exhibits and are incorporated by reference, but the information is being furnished under Regulation FD rather than filed for liability purposes. This 8-K does not itself include numerical trial results, but directs investors to the accompanying materials for detailed clinical data.
T. Rowe Price Associates, Inc. reported beneficial ownership of 10,041,900 shares of Alkermes plc common stock, representing 6.1% of the class as of June 30, 2025. The firm reports sole voting power for 9,983,207 shares and sole dispositive power for 10,041,900 shares on a Schedule 13G/A.
The filing identifies T. Rowe Price as an investment adviser filing under Rule 13d-1(b) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The Schedule is signed by Ellen York, Vice President, dated August 14, 2025.